LDS/Medical Tests/MyProstateScore 2.0 (MPS2) for Prostate Cancer Early Detection

MyProstateScore 2.0 (MPS2) for Prostate Cancer Early Detection

Prostate cancer remains a leading cause of cancer-related mortality in men. Conventional serum PSA testing, while prostate-specific, often leads to unnecessary invasive biopsies due to its limited specificity.

MyProstateScore 2.0 (MPS2) is a urine-based molecular test developed by University of Michigan researchers, offered by LynxDx, that estimates the risk of clinically significant prostate cancer (Grade Group ≥2; Gleason score ≥7). It detects the TMPRSS2:ERG (T2:ERG) gene fusion, a hallmark in prostate cancer, along with 17 additional genetic biomarkers.

The test uses quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to assess gene expression from urine samples collected either with or without digital rectal examination (DRE).

MPS2 provides a risk score predicting the likelihood of detecting clinically significant prostate cancer. It offers a negative predictive value (NPV) up to 99%, enabling many men to avoid unnecessary biopsies.

Samples are stable at room temperature, allowing collection in both clinical and home settings.

  • Serves as triage for prostate biopsy in for both previous negative biopsy and biopsy naïve patients
  • Assisting in biopsy decision-making, particularly in men with elevated PSA or abnormal DRE findings
Positive Results indicate the presence of T2:ERG fusion and/or elevated expression of associated biomarkers suggesting a higher likelihood of clinically significant prostate cancer. Biopsy is recommended based on clinical judgment. Negative Results indicate absence or low levels of prostate cancer-specific biomarkers suggesting a low probability of clinically significant prostate cancer. Biopsy may be deferred or avoided based on clinical context. Note: Results should always be interpreted alongside other clinical information, including PSA levels, DRE findings, imaging studies, and patient history.

Negative: Below established cutoff threshold (indicating low risk)

Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) with RNA-based molecular profiling from post-DRE urine specimens.

Post-DRE (Digital Rectal Examination) urine, 10 mL collected in sterile screw-capped container.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
Free PSA, PCA3, ExoDx, prostate biopsy.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login